FDA approves tafluprost for lowering IOP

February 15, 2012

The FDA has approved tafluprost ophthalmic solution 0.0015%(Zioptan, Merck), a preservative-free prostaglandin analog, for reducing elevated IOP in patients with open-angle glaucoma or ocular hypertension.

Whitehouse Station, NJ-The FDA has approved tafluprost ophthalmic solution 0.0015% (Zioptan, Merck), a preservative-free prostaglandin analog, for reducing elevated IOP in patients with open-angle glaucoma or ocular hypertension.

The agency based its approval on efficacy and safety results from five controlled clinical studies in a total of 905 patients. In the studies, of up to 2 years in duration, tafluprost dosed once daily in the evening lowered IOP at 3 and 6 months by 6 to 8 mm Hg and 5 to 8 mm Hg, respectively, from a baseline IOP of 23 to 26 mm Hg. Both preservative-containing and preservative-free formulations of tafluprost were used in the clinical studies.

“Prostaglandin analogs are often used as a first line of treatment to lower IOP in patients with open-angle glaucoma,” said George L. Spaeth, MD, of the Wills Eye Institute, Philadelphia. “The approval of [tafluprost ophthalmic solution] will provide a new, effective option to lower IOP. I anticipate using [tafluprost] in many of these patients in my practice.”

Merck anticipates that tafluprost will be available to customers next month.

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Content:

News